Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Medical Economics

• Publication date

  2013-02-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.3111/13696998.2012.737392PMID 23035627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias

  2010cited by this paper
• [A proposed guideline for economic evaluation of health technologies].

  2010cited by this paper
• Late (Complicated) Parkinson's Disease

  2010cited by this paper
• Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial

  2010cited by this paper
• [Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease].

  2009cited by this paper
• Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.

  2009cited by this paper
• Bilateral deep brain stimulation versus best medical therapy for patients with advanced Parkinson’s disease

  2009cited by this paper
• Revisión de la evidencia económica sobre el uso de la estimulación cerebral profunda en la enfermedad de Parkinson avanzada

  2009cited by this paper
• Deep brain stimulation for Parkinson's disease: Australian referral guidelines.

  2009cited by this paper
• Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.

  2009cited by this paper
• Parkinson’s disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion

  2008cited by this paper
• Duodenal levodopa infusion for the treatment of Parkinson’s disease

  2007cited by this paper
• Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome

  2007cited by this paper
• Prospective comparative study on cost‐effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease

  2007cited by this paper
• Bilateral subthalamic nucleus stimulation in advanced Parkinson’s disease

  2007cited by this paper
• Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

  2007cited by this paper
• Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson’s disease

  2006cited by this paper
• Subthalamic nucleus deep brain stimulation: Summary and meta‐analysis of outcomes

  2006cited by this paper
• Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus

  2006cited by this paper
• Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

  2006cited by this paper
• Using the Delphi technique in economic evaluation: time to revisit the oracle?

  2006cited by this paper
• [The prevalence and pharmacological cost of Parkinson's disease in Spain].

  2006cited by this paper
• A randomized trial of deep-brain stimulation for Parkinson's disease.

  2006cited by this paper
• Deep brain stimulation in late stage Parkinson’s disease: a retrospective cost analysis in Germany

  2005cited by this paper
• Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up

  2005cited by this paper
• Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges

  2005cited by this paper
• Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.

  2005cited by this paper
• Prevalence of Parkinson’s disease and other types of Parkinsonism

  2004cited by this paper
• Longevity of Batteries in Internal Pulse Generators Used for Deep Brain Stimulation

  2004cited by this paper
• Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.

  2004cited by this paper
• [Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase].

  2003cited by this paper
• Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease.

  2003cited by this paper
• Estimating the costs of surgical innovations: The case for subthalamic nucleus stimulation in the treatment of advanced Parkinson's disease

  2003cited by this paper
• Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain

  2003cited by this paper
• Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus

  2002cited by this paper
• Prevalence of Parkinson's disease in Cantalejo, Spain: A door‐to‐door survey

  2002cited by this paper
• Relevance of motor complications in Parkinson’s disease

  2002cited by this paper
• Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients

  2002cited by this paper
• Nonparametric Statistical Methods, 2nd, Ed.

  2001cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• Deep brain stimulation in the treatment of Parkinson’s disease

  2001cited by this paper
• Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up

  1998cited by this paper
• Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.

  1998cited by this paper
• Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation

  1995cited by this paper
• Nonparametric Statistical Methods

  1974cited by this paper

• Budget impact analysis of deep brain stimulation devices with different longevity in Parkinson's disease: insights from real-world data

  2026cites this paper
• Improving Parkinson’s disease management through wearable technology: A cost-benefit perspective

  2025cites this paper
• El Coste de la Calidad de Vida en la Enfermedad de Parkinson Avanzada: Estrategias Eficientes Para Abordar la Enfermedad

  2025cites this paper
• Global Economic Evaluation of the Reported Costs of Deep Brain Stimulation

  2024cites this paper
• A 4‐Year Follow‐Up of Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Parkinson's Disease

  2024cites this paper
• Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease

  2024cites this paper
• Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study

  2023cites this paper
• La perfusion sous-cutanée d’apomorphine : recommandations à destination des acteurs de santé pour une installation à l’hôpital ou à domicile

  2023cites this paper
• The Natural Neuroprotective Compounds Used in the 6-Hydroxydopamine-Induced Parkinson's Disease in Zebrafish: The Current Applications and Perspectives.

  2022cites this paper
• Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson’s disease

  2021cites this paper
• Direct Cost of Parkinson's Disease: A Real-World Data Study of Second-Line Therapies

  2020cites this paper
• Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review

  2020cites this paper
• Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson’s disease - the INfusion VErsus STimulation (INVEST) study

  2020cites this paper
• Systematic review of the pharmacoeconomics of Parkinson disease medications

  2019influential citation
• Deep Brain Stimulation in Parkinson's Disease

  2019cites this paper
• Cell therapy for Parkinson′s disease is coming of age: current challenges and future prospects with a focus on immunomodulation

  2019cites this paper
• Automating levodopa dosing schedules for Parkinson's disease

  2019cites this paper
• Battery longevity of neurostimulators in Parkinson disease: A historic cohort study.

  2019cites this paper
• Ablative surgery for Parkinson's disease: Is there still a role for pallidotomy in the deep brain stimulation era?

  2017cites this paper
• Optimizing levodopa dosing routines for Parkinson’s disease

  2017cites this paper
• Use of advanced therapies for Parkinson's disease in Norway.

  2017cites this paper
• Costly treatment - equal treatment?

  2017cites this paper
• Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience

  2017cites this paper
• [Practical use of continuous apomorphine infusion via pump].

  2017cites this paper
• Valproic Acid Protects Primary Dopamine Neurons from MPP+-Induced Neurotoxicity: Involvement of GSK3β Phosphorylation by Akt and ERK through the Mitochondrial Intrinsic Apoptotic Pathway

  2017cites this paper
• Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline

  2016cites this paper
• Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia

  2016cites this paper
• Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.

  2016cites this paper
• Deep Brain Stimulation for Parkinson’s Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis

  2016cites this paper
• The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain.

  2016cites this paper
• The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain

  2016cites this paper
• Infusion treatments and deep brain stimulation in Parkinson's Disease: The role of nursing.

  2016cites this paper
• ESTIMULACIÓN CEREBRAL PROFUNDA EN TRASTORNOS NEUROLÓGICOS Y PSIQUIÁTRICOS

  2016cites this paper
• Ethics of Functional Neurosurgery

  2015cites this paper
• Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany

  2015cites this paper
• Estimating the direct and indirect costs associated with Parkinson’s disease

  2015cites this paper
• The medical treatment of patients with Parkinson's disease receiving subthalamic neurostimulation.

  2015cites this paper
• Letter to the editor Reply: Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s Disease in the UK and Germany

  2015cites this paper
• More than just a movement disorder

  2015cites this paper
• Re: Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s Disease in the UK and Germany

  2015cites this paper
• Accuracy of Robotic Guided Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s Disease

  2015cites this paper
• Principle and technology

  2014cites this paper
• Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients

  2014cites this paper
• Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease

  2013cites this paper
• When the going gets tough: how to select patients with Parkinson's disease for advanced therapies

  2013cites this paper